FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2574279203> ?p ?o ?g. }

• W2574279203 abstract "Abstract Abstract 2807 Poster Board II-783 Enumeration of circulating blood cell populations with endothelial– or progenitor-like phenotype has been proposed as surrogate biomarker for tumor response to anti-angiogenic or conventional therapies and is currently being applied in multiple clinical studies. Moreover, recent preclinical studies have suggested a role of circulating progenitor cell populations (EPCs or CPCs) in tumor re-growth after therapy. Cytotoxic agents administered at the maximal tolerated dose induce a rapid mobilization of EPC during therapy-free intervals, possibly resulting in paradoxal rebound angiogenesis (Shaked et al. Cancer Cell 2008;14,263). This EPC mobilization can be inhibited by combination therapy with anti-angiogenic agents, resulting into sustained EC suppression. Multiple myeloma (MM) is characterized by increased angiogenesis in the BM. The effect of novel agents such as Bortezomib and Thalidomide (THAL) is partially mediated by inhibition of BM angiogenesis. In the present study, we evaluated CD31+CD45– and CD34+CD133+CD45dim circulating cell numbers in MM patients and monitored their kinetics in patients treated with MEL, Bortezomib or THAL. Cells were enumerated among blood mononuclear cells by multicolor flow cytometry according to a standardized protocol (Duda et al. Nat Protoc 2007;2,805) at baseline and at multiple time points during treatment. Baseline levels and changes over time were correlated with response and survival. At baseline, MM patients (n=71) show significant higher CD31+CD45– and CD34+CD133+CD45dim circulating cell levels compared to healthy individuals (n=10) (7 and 2,5-fold increase, respectively, p<0,02). Moreover, both CD31+CD45– and CD34+CD133+CD45dim circulating cell numbers where higher in patients with active versus non-active disease (1,9 and 4 fold increase, p<0,05) and in patients with relapsed/refractory disease, versus at diagnosis (2,1 and 2 fold increase, p<0,05), reflecting increased angiogenesis associated with disease progression. Treatment with Bortezomib or THAL resulted in a rapid and sustained decline in CD31+CD45– and CD34+CD133+CD45dim circulating cell numbers, whereas treatment with MEL induced an initial decrease followed by a transient, significant (up to 20-fold) increase in CD34+CD133+CD45dim circulating cell levels at the end of each cycle. This increase was even more pronounced when hematopoietic growth factors were used. Interestingly, patients treated with MEL in combination with Bortezomib or THAL showed a less pronounced CD34+CD133+CD45dim circulating cell increase than with MEL alone, suggesting that Bortezomib and THAL inhibited MEL-induced progenitor cell mobilization. In conclusion, the findings in this study show that CD31+CD45– and CD34+CD133+CD45dim circulating cell levels are increased in MM patients and correlate with disease progression. In addition, these results suggest that CD31+CD45– and CD34+CD133+CD45dim circulating cell enumeration may represent a useful angiogenesis biomarker to assess prognosis or treatment responses in MM. Treatment with Bortezomib and THAL resulted in a sustained decrease of CD34+CD133+CD45dim circulating cell levels and inhibition of MEL-induced mobilization of these progenitor cells. These findings may reflect an additional mechanism for the anti-angiogenic and chemosensitizing effects of Bortezomib and THAL, resulting into increased anti-tumoral efficacy and clinical benefit as shown in recent randomized trials. Disclosures: No relevant conflicts of interest to declare." @default.
• W2574279203 created "2017-01-26" @default.
• W2574279203 creator A5014026887 @default.
• W2574279203 creator A5022702941 @default.
• W2574279203 creator A5028855307 @default.
• W2574279203 creator A5048560248 @default.
• W2574279203 creator A5051698029 @default.
• W2574279203 creator A5053222814 @default.
• W2574279203 date "2009-11-20" @default.
• W2574279203 modified "2023-09-26" @default.
• W2574279203 title "Changes in Blood Circulating Cell Populations May Reflect the Anti-Angiogenic and Chemosensitizing Effects of Bortezomib and Thalidomide Treatment in Patients with Multiple Myelomatreatment in Patients with Multiple Myeloma." @default.
• W2574279203 doi "https://doi.org/10.1182/blood.v114.22.2807.2807" @default.
• W2574279203 hasPublicationYear "2009" @default.
• W2574279203 type Work @default.
• W2574279203 sameAs 2574279203 @default.
• W2574279203 citedByCount "0" @default.
• W2574279203 crossrefType "journal-article" @default.
• W2574279203 hasAuthorship W2574279203A5014026887 @default.
• W2574279203 hasAuthorship W2574279203A5022702941 @default.
• W2574279203 hasAuthorship W2574279203A5028855307 @default.
• W2574279203 hasAuthorship W2574279203A5048560248 @default.
• W2574279203 hasAuthorship W2574279203A5051698029 @default.
• W2574279203 hasAuthorship W2574279203A5053222814 @default.
• W2574279203 hasConcept C10205521 @default.
• W2574279203 hasConcept C126322002 @default.
• W2574279203 hasConcept C137061746 @default.
• W2574279203 hasConcept C143998085 @default.
• W2574279203 hasConcept C201750760 @default.
• W2574279203 hasConcept C202751555 @default.
• W2574279203 hasConcept C203014093 @default.
• W2574279203 hasConcept C2776364478 @default.
• W2574279203 hasConcept C2777478702 @default.
• W2574279203 hasConcept C2778939058 @default.
• W2574279203 hasConcept C2779609412 @default.
• W2574279203 hasConcept C2780394083 @default.
• W2574279203 hasConcept C28328180 @default.
• W2574279203 hasConcept C502942594 @default.
• W2574279203 hasConcept C54355233 @default.
• W2574279203 hasConcept C55493867 @default.
• W2574279203 hasConcept C71924100 @default.
• W2574279203 hasConcept C86803240 @default.
• W2574279203 hasConcept C98274493 @default.
• W2574279203 hasConceptScore W2574279203C10205521 @default.
• W2574279203 hasConceptScore W2574279203C126322002 @default.
• W2574279203 hasConceptScore W2574279203C137061746 @default.
• W2574279203 hasConceptScore W2574279203C143998085 @default.
• W2574279203 hasConceptScore W2574279203C201750760 @default.
• W2574279203 hasConceptScore W2574279203C202751555 @default.
• W2574279203 hasConceptScore W2574279203C203014093 @default.
• W2574279203 hasConceptScore W2574279203C2776364478 @default.
• W2574279203 hasConceptScore W2574279203C2777478702 @default.
• W2574279203 hasConceptScore W2574279203C2778939058 @default.
• W2574279203 hasConceptScore W2574279203C2779609412 @default.
• W2574279203 hasConceptScore W2574279203C2780394083 @default.
• W2574279203 hasConceptScore W2574279203C28328180 @default.
• W2574279203 hasConceptScore W2574279203C502942594 @default.
• W2574279203 hasConceptScore W2574279203C54355233 @default.
• W2574279203 hasConceptScore W2574279203C55493867 @default.
• W2574279203 hasConceptScore W2574279203C71924100 @default.
• W2574279203 hasConceptScore W2574279203C86803240 @default.
• W2574279203 hasConceptScore W2574279203C98274493 @default.
• W2574279203 hasLocation W25742792031 @default.
• W2574279203 hasOpenAccess W2574279203 @default.
• W2574279203 hasPrimaryLocation W25742792031 @default.
• W2574279203 hasRelatedWork W11032802 @default.
• W2574279203 hasRelatedWork W1872188472 @default.
• W2574279203 hasRelatedWork W1990136541 @default.
• W2574279203 hasRelatedWork W2085011517 @default.
• W2574279203 hasRelatedWork W2131708161 @default.
• W2574279203 hasRelatedWork W2265336044 @default.
• W2574279203 hasRelatedWork W2461939669 @default.
• W2574279203 hasRelatedWork W2486093233 @default.
• W2574279203 hasRelatedWork W2556224372 @default.
• W2574279203 hasRelatedWork W2565282098 @default.
• W2574279203 hasRelatedWork W2573451211 @default.
• W2574279203 hasRelatedWork W2595353436 @default.
• W2574279203 hasRelatedWork W2912175206 @default.
• W2574279203 hasRelatedWork W2954592222 @default.
• W2574279203 hasRelatedWork W2970632109 @default.
• W2574279203 hasRelatedWork W2978887204 @default.
• W2574279203 hasRelatedWork W2980243776 @default.
• W2574279203 hasRelatedWork W2981244806 @default.
• W2574279203 hasRelatedWork W3113236405 @default.
• W2574279203 hasRelatedWork W3169865581 @default.
• W2574279203 isParatext "false" @default.
• W2574279203 isRetracted "false" @default.
• W2574279203 magId "2574279203" @default.
• W2574279203 workType "article" @default.